التداول ينطوي على مخاطر
الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
التداول ينطوي على مخاطر
الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
UCB SA
Open
Sector Healthcare
174.15 2.47
Overview
Share price change
24h
Min
168.6
Max
174.55
Income | 104M |
|---|---|
Sales | 127M 2.8B |
P/E Sector Avg | 78.783 94.998 |
EPS | 2.09 |
Profit margin | 3.728 |
EBITDA | 652M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +19.23 upside |
Market Cap | -2.4B 32B |
|---|---|
Previous open | 171.68 |
Previous close | 174.15 |
News Sentiment
By Acuity
72%
28%
349 / 392 Ranking in Healthcare
UCB SA Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
UCB SA Forecast
Price Target
By TipRanks
19.23% upside
12 Months Forecast
Average 94.86 EUR 19.23%
High 125 EUR
Low 74 EUR
Based on 7 Wall Street analysts offering 12 month price targets forUCB SA - Dist in the last 3 months.
Sentiment
By Acuity
349 / 392 Ranking in Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
EBITDA
Operating profit
$
About UCB SA
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
